Reducing the burden of glandular carcinomas of the uterine cervix

American Journal of Obstetrics and Gynecology

Volumn 197, Issue 6, 2007, Pages 566-571

  Herzog, Thomas J ^a   Monk, Bradley J ^b  

^a Howard Hughes Medical Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cervical adenocarcinoma; cervical cancer; cervical screening; HPV; vaccine

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADENOCARCINOMA; CANCER INCIDENCE; CANCER SCREENING; CARCINOGENESIS; DIAGNOSTIC TEST; FEMALE GENITAL TRACT INFECTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; PAPANICOLAOU TEST; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCREENING TEST; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS INFECTION; VIRUS ONCOGENE; VIRUS TYPING;

ADENOCARCINOMA; CANCER VACCINES; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 36448934173     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.08.055     Document Type: Review

References (58)

1. Sankaranarayanan R., and Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20 (2006) 207-225
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
3. Ries L, Harkins D, Krapcho M, et al, editors. SEER cancer statistics review, 1975-2004, National Cancer Institute. Bethesda, MD, based on November 2005 SEER data submission, posted to the SEER web site, 2007.
4. Mahdavi A., and Monk B.J. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 10 (2005) 528-538
5. Ries L, Harkins D, Krapcho M, et al. SEER cancer statistics review, 1975-2004, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/cgibin/csr/1975_2004/search.pl results. Accessed Aug. 2, 2007
6. Smith H.O., Tiffany M.F., Qualls C.R., and Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States: a 24-year population-based study. Gynecol Oncol 78 (2000) 97-105
7. Wang S.S., Sherman M.E., Hildesheim A., Lacey Jr. J.V., and Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 100 (2004) 1035-1044
8. Zheng T., Holford T.R., Ma Z., et al. The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. Int J Epidemiol 25 (1996) 252-258
9. Liu S., Semenciw R., and Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ 164 (2001) 1151-1152
10. Sherman M.E., Wang S.S., Carreon J., and Devesa S.S. Mortality trends for cervical squamous and adenocarcinoma in the United States: relation to incidence and survival. Cancer 103 (2005) 1258-1264
11. Krane J.F., Granter S.R., Trask C.E., Hogan C.L., and Lee K.R. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer 93 (2001) 8-15
12. Lee K.R., Minter L.J., and Granter S.R. Papanicolaou smear sensitivity for adenocarcinoma in situ of the cervix: a study of 34 cases. Am J Clin Pathol 107 (1997) 30-35
13. Zappa M., Visioli C.B., Ciatto S., Iossa A., Paci E., and Sasieni P. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer 90 (2004) 1784-1786
14. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
15. Munoz N., Bosch F.X., Castellsague X., et al. Against which human papillomavirus types shall we vaccinate and screen?. The international perspective. Int J Cancer 111 (2004) 278-285
16. Centers for Disease Control. Genital HPV - CDC Fact Sheet (2004)
17. Cuschieri K.S., Cubie H.A., Whitley M.W., et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 58 (2005) 946-950
18. Schlecht N.F., Kulaga S., Robitaille J., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286 (2001) 3106-3114
19. Ho G.Y., Bierman R., Beardsley L., Chang C.J., and Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 (1998) 423-428
20. Carter J.J., Koutsky L.A., Hughes J.P., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181 (2000) 1911-1919
21. Viscidi R.P., Snyder B., Cu-Uvin S., et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 14 (2005) 283-288
22. Bosch F.X., Manos M.M., Munoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective: international biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 87 (1995) 796-802
23. Bosch F.X., and de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer: burden and assessment of causality. J Natl Cancer Inst Monogr 31 (2003) 3-13
24. Castellsague X., Diaz M., de Sanjose S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98 (2006) 303-315
25. Andersson S., Rylander E., Larson B., et al. Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol Rep 10 (2003) 175-179
26. Jaworski R.C., Pacey N.F., Greenberg M.L., and Osborn R.A. The histologic diagnosis of adenocarcinoma in situ and related lesions of the cervix uteri: adenocarcinoma in situ. Cancer 61 (1988) 1171-1181
27. Zaino R.J. Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 21 (2002) 314-326
28. Plaxe S.C., and Saltzstein S.L. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol 75 (1999) 55-61
29. Lee K.R., and Flynn C.E. Early invasive adenocarcinoma of the cervix. Cancer 89 (2000) 1048-1055
30. Ruba S., Schoolland M., Allpress S., and Sterrett G. Adenocarcinoma in situ of the uterine cervix: screening and diagnostic errors in Papanicolaou smears. Cancer 102 (2004) 280-287
31. Stoler M.H. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol 19 (2000) 16-28
32. Eifel P.J., Burke T.W., Morris M., and Smith T.L. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 59 (1995) 38-44
33. Burger R.A., Monk B.J., Kurosaki T., et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 88 (1996) 1361-1368
34. Im S.S., Wilczynski S.P., Burger R.A., and Monk B.J. Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion. Clin Cancer Res 9 (2003) 4145-4150
35. Shingleton H.M., Bell M.C., Fremgen A., et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix?. Cancer 76 (1995) 1948-1955
36. Solomon D., Davey D., Kurman R., et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287 (2002) 2114-2119
37. Sharpless K.E., Schnatz P.F., Mandavilli S., Greene J.F., and Sorosky J.I. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol 105 (2005) 494-500
38. Saslow D., Runowicz C.D., Solomon D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52 (2002) 342-362
39. Schorge J.O., Hossein Saboorian M., Hynan L., and Ashfaq R. ThinPrep detection of cervical and endometrial adenocarcinoma: a retrospective cohort study. Cancer 96 (2002) 338-343
40. Ashfaq R., Gibbons D., Vela C., Saboorian M.H., and Iliya F. ThinPrep Pap test: accuracy for glandular disease. Acta Cytol 43 (1999) 81-85
41. Bai H., Sung C.J., and Steinhoff M.M. ThinPrep Pap test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol 23 (2000) 19-22
42. Gravitt P.E., and Jamshidi R. Diagnosis and management of oncogenic cervical human papillomavirus infection. Infect Dis Clin North Am 19 (2005) 439-458
43. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol (2007) [in press]
44. Sharpless K.E., Schnatz P.F., Mandavilli S., Greene J.F., and Sorosky J.I. Lack of adherence to practice guidelines for women with atypical glandular cells on cervical cytology. Obstet Gynecol 105 (2005) 501-506
45. Kalir T., Simsir A., Demopoulos H.B., and Demopoulos R.I. Obstacles to the early detection of endocervical adenocarcinoma. Int J Gynecol Pathol 24 (2005) 399-403
46. Saint M., Gildengorin G., and Sawaya G.F. Current cervical neoplasia screening practices of obstetrician/gynecologists in the United States. Am J Obstet Gynecol 192 (2005) 414-421
47. FDA approves expanded use of HPV test. US Food and Drug Administration. 2003. Available at: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00890.html. Accessed Aug. 3, 2007.
48. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., and Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 suppl 3 (2006) S78-S89
49. Monk B.J., Cook N., Ahn C., Vasilev S.A., Berman M.L., and Wilczynski S.P. Comparison of the polymerase chain reaction and Southern blot analysis in detecting and typing human papilloma virus deoxyribonucleic acid in tumors of the lower female genital tract. Diagn Mol Pathol 3 (1994) 283-291
50. Franco E.L., and Harper D.M. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 23 (2005) 2388-2394
51. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
52. Villa L.L., Costa R.L., Petta C.A., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
53. Brown D.R., Shew M.L., Qadadri B., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191 (2005) 182-192
54. GlaxoSmithKline submits biologics license application to U.S. Food and Drug Administration for Cervarix, 2007. Available at: medicalnewstoday.com/articles/66737.php. Accessed Aug. 13, 2007.
55. Giannini S.L., Hanon E., Moris P., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006) 5937-5949
56. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
57. Gall S., Teixeira J., Wheeler C., et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine (2007). http://www.abstractsonline.com/viewer/SearchResults.asp Proceedings of the AACR Annual Meeting 2007. Available at: www.abstractsonline.com/viewer/SearchResults.asp. Accessed Aug. 11, 2007.
58. Merck submits new cross-protection data for GARDASIL to the FDA and seeks new indications for vaginal and vulvar cancers. Press release, 2007. Available at: http://medicalnewstoday.com/articles/66235.php. Accessed Aug. 3, 2007.